SEC Tracker
Get the app

Galecto DMRA

Galecto FY 2022: net loss $61.6M; diluted EPS −$60.75

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Galecto reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$61.6MAgainst −$51.8M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS−$60.75Against −$51.25 in FY 2021. Split-adjusted, as the tables show it; the filing reported −$2.4310-K income statement, on EDGAR
  3. Cash and cash equivalents$32.8M−48% from $62.6M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$42.9MAgainst −$52.3M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Galecto files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Synlogic SYBX public float $4M, Jun 30, 2025
  2. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  3. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  4. Soligenix SNGX public float $5M, Jun 30, 2025
  5. Target Group CBDY public float $5M, Jun 30, 2025